Stockscreener 앱 받기
20.50
151.23%
12.34
시간 외 거래:
15.67
-4.83
-23.56%
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals releases second episode of ‘Living with Netherton’ series - TipRanks
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com India
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com UK
Quoin seeks patent for skin disease treatment QRX003 - Investing.com
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Quoin Pharmaceuticals sets terms for $6.5 million offering - Investing.com
Major Indexes Muted Following Strong Jobs Report - Schaeffer's Investment Research
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada - Yahoo Finance
Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis - MarketBeat
Quoin Pharmaceuticals Ltd DRC Stock Price Today | NASDAQ: QNRX Live - Investing.com
Quoin Pharmaceuticals Completes Merger and Will Commence Trading on Nasdaq Capital Market under Ticker Symbol “QNRX” - The Globe and Mail
Cellect Announces Positive Clinical Results15.10.18News - Ariva
Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technologythe ApoGraft™ - Ariva
Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results - Ariva
5.74%
자본화:
|
볼륨(24시간):